This EOM Pharmaceuticals website may contain information, news, and/or press releases, the content of which is accurate or current only as of the date of the particular information, news, press release, or posting. EOM does not update press releases once they have been made public.
MONTVALE, N.J. – July 20, 2021 — EOM Pharmaceuticals, Inc., a privately-held, clinical-stage company, today announced the appointment of Frank L. Douglas, Ph.D., M.D., to Scientific Advisor. Dr. Douglas will be responsible for guiding the company’s clinical and scientific strategies for EOM lead candidate EOM613, as well as forming and chairing the EOM Scientific Advisory […]
MONTVALE, N.J. – December 23, 2020 — EOM Pharmaceuticals, Inc., a privately held, clinical-stage company, today announced it has filed a pre-Investigational New Drug Application (pre-IND) meeting request and complete pre-IND briefing documents with the U.S. Food and Drug Administration (FDA) to discuss the company’s plans to evaluate the safety and efficacy of its dual-acting, […]
MONTVALE, NEW JERSEY – December 17, 2020 — EOM Pharmaceuticals, a privately held, clinical-stage company, announced today the appointment of business veteran Wayne I. Danson, CPA, as Chief Financial Officer and Treasurer. Mr. Danson will be responsible for leading the Company’s financial operations including financial planning and analysis, capital markets, investor relations, accounting, tax and […]